


PHARMACEUTICAL 2020



VERTEX PHARMACEUTICALS INC MA Rank 18 of 362







PHARMACEUTICAL 2020



VERTEX PHARMACEUTICALS INC MA Rank 18 of 362



The relative strengths and weaknesses of VERTEX PHARMACEUTICALS INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VERTEX PHARMACEUTICALS INC MA compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 407% points. The greatest weakness of VERTEX PHARMACEUTICALS INC MA is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 217%, being 520% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	4,822,829
Cost of Goods Sold	547,758
Intangible Assets	1,402,158
Liabilities, Current	1,334,827
Liabilities, Non-Current	183,318
Other Assets	1,335,393
Other Compr. Net Income	-2,632
Other Expenses	281,070
Other Liabilities	715,076
Other Net Income	255,855
Property and Equipment	758,085
Research and Development	1,754,540
Revenues	4,162,821
Selling, General and Administrative Expense	658,498

Output Variable	Value in 1000 USD
Assets	8,318,465
Liabilities	2,233,221
Expenses	3,241,866
Stockholders Equity	6,085,244
Net Income	1,176,810
Comprehensive Net Income	1,175,494
Economic Capital Ratio	217%